UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics

Mehra, Vedika; Chhetri, Jyoti Bikram; Ali, Samira; Roddie, Claire; (2023) The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics. Biology , 12 (11) , Article 1419. 10.3390/biology12111419. Green open access

[thumbnail of Roddie_he Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics_VoR.pdf]
Preview
Text
Roddie_he Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics_VoR.pdf - Published Version

Download (1MB) | Preview

Abstract

Adoptive cell therapy (ACT) has transformed the treatment landscape for cancer and infectious disease through the investigational use of chimeric antigen receptor T-cells (CAR-Ts), tumour-infiltrating lymphocytes (TILs) and viral-specific T-cells (VSTs). Whilst these represent breakthrough treatments, there are subsets of patients who fail to respond to autologous ACT products. This is frequently due to impaired patient T-cell function or “fitness” as a consequence of prior treatments and age, and can be exacerbated by complex manufacturing protocols. Further, the manufacture of autologous, patient-specific products is time-consuming, expensive and non-standardised. Induced pluripotent stem cells (iPSCs) as an allogeneic alternative to patient-specific products can potentially overcome the issues outlined above. iPSC technology provides an unlimited source of rejuvenated iPSC-derived T-cells (T-iPSCs) or natural killer (NK) cells (NK-iPSCs), and in the context of the growing field of allogeneic ACT, iPSCs have enormous potential as a platform for generating off-the-shelf, standardised, “fit” therapeutics for patients. In this review, we evaluate current and future applications of iPSC technology in the CAR-T/NK, TIL and VST space. We discuss current and next-generation iPSC manufacturing protocols, and report on current iPSC-based adoptive therapy clinical trials to elucidate the potential of this technology as the future of ACT.

Type: Article
Title: The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics
Location: Switzerland
Open access status: An open access version is available from UCL Discovery
DOI: 10.3390/biology12111419
Publisher version: https://doi.org/10.3390/biology12111419
Language: English
Additional information: Copyright © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/4.0/).
Keywords: Induced pluripotent stem cells (iPSCs); chimeric antigen receptor T-cells (CAR-Ts); tumour-infiltrating lymphocytes (TILs); natural killer (NK) cells; virus-specific T-cells (VSTs); adoptive cell therapy (ACT); manufacturing; off-the-shelf; reprogramming
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Haematology
URI: https://discovery.ucl.ac.uk/id/eprint/10183072
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item